Anders Karlsson
Idogen's study approved in Norway and Sweden
Idogen has now received the go-ahead from both the Swedish and Norwegian Medicines Agencies to initiate a clinical phase I/IIa study with...
BioStock Studio: Idogen receives approval for Phase I/IIa study with IDO 8
Yesterday, the cell therapy company Idogen announced that the Swedish Medical Products Agency has approved its...
BioStock Studio: Idogen approaches clinical trial
Cell therapy company Idogen is approaching the start of a clinical...
BioStock Studio: Idogen's CEO comments on the issue outcome and the next important steps
On Monday, Idogen presented the outcome of the rights issue which...
Idogen's CEO looks forward to the next step in hemophilia
Idogen has recently submitted a clinical trial application...
BioStock Studio: Idogen has optimized IDO 8 for clinical phase
Recently, Idogen announced that they have optimized the manufacturing process...
Idogen passes important milestone ahead of clinical phase
Idogen has optimized the GMP manufacturing process in order to maximize...
BioStock Studio: High activity during Q3 for Idogen
Idogen is now in the final phase of preparations
Eight CEOs on their expectations for BIO-Europe
These days it is time again for BIO-Europe,...
BioStock Studio: Idogen's CEO comments on the quarterly report
Yesterday Idogen published its second quarter report and...
Idogen's CEO on World Transplant Day and IDO T against organ rejection
Sunday, June 6th is not only Sweden's...
BioStock Studio: Idogen's CEO on the Q1 report
Anders Karlsson, CEO of the biotechnology company Idogen, visited BioStock's...